Astellas, Sutro partner to develop novel iADCs for cancer treatment
The partnership leverages the cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Jun 22
The partnership leverages the cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer…
28 Jun 22
The expanded approval is based on data from the JUNIPERA trial, which showed that Cosentyx reduced the risk…
27 Jun 22
The FDA approval was based on data from the Phase 3 TRANSFORM trial and Phase 2 PILOT study,…
24 Jun 22
The vaccine has also been recommended by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human…
23 Jun 22
The drug combination was indicated for metastatic solid tumours with BRAF V600E mutations in adults and children aged…
22 Jun 22
A modified panel of CAFC reversed the decision upholding the validity of the Gilenya dosing regimen patent granted…
21 Jun 22
The NMPA approval is based on the interim analysis of the Phase 3 ORIENT-15 clinical trial, in which…
21 Jun 22
Pfizer and Valneva have updated the terms of their existing collaboration and license agreement for the development of…
17 Jun 22
Exelixis is enabled to expand its biotherapeutics pipeline by selecting antibody candidates against targets identified using BioInvent’s immuno-oncology…
17 Jun 22
In the study, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation…